| OAA0403 | In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014 | Oral abstract session with live Q&A | Strategies to reduce/eliminate viral reservoirs |
| OAA0404 | AZD5582 and SIV Env-targeting rhesus monoclonal antibodies (RhmAbs) ± N-803 in SIV-infected ART-suppressed rhesus macaques | Oral abstract session with live Q&A | Strategies to reduce/eliminate viral reservoirs |
| OAA0405 | Temsavir treatment of HIV-1-infected cells decreases envelope glycoproteins recognition by broadly-neutralizing antibodies | Oral abstract session with live Q&A | Immunotherapy (including broadly neutralizing antibodies) |
| OAB0102 | Chronic injection opioid use increases the systemic inflammation and T cell immune activation in virally suppressed people living with HIV | Oral abstract session with live Q&A | Clinical issues in people who use drugs |
| OAB0103 | Impact of gender identity- and HIV-related stigmas and psychosocial resources on mental health and alcohol use among transgender women newly diagnosed with HIV in India: a longitudinal cohort study | Oral abstract session with live Q&A | Mental health (including depression and psychiatric manifestations) and HIV |
| OAB0104 | Forty-eight week outcomes of a combined cognitive behavioral therapy and medication management algorithm for treatment of depression among youth living with HIV in the United States (IMPAACT 2002) | Oral abstract session with live Q&A | Mental health (including depression and psychiatric manifestations) and HIV |
| OAB0105 | Long-term risk of hospitalization and chronic disease among children who were HIV-exposed uninfected (cHEU) compared to population controls in Montreal, Canada | Oral abstract session with live Q&A | HIV-exposed uninfected children |
| OAB0202 | The fast and the continuous: dolutegravir-based antiretroviral therapy achieves impressive viral load suppression in CALHIV in the short- and long-term | Oral abstract session with live Q&A | ARV management strategies in paediatric and adolescent populations |
| OAB0203 | Optimal timing for ART initiation in ART-naive children and adolescents living with HIV following the diagnosis of HIV-associated TB | Oral abstract session with live Q&A | TB/HIV co-infection in paediatric and adolescent populations (including treatment and prevention) |
| OAB0204 | Subcortical brain volumes of children who are HIV-exposed and uninfected in the first three years of life: a South African birth cohort study | Oral abstract session with live Q&A | HIV-exposed uninfected children |